IRadimed stock holds near 52-week high as investors watch growth metrics

IRadimed stock is trading close to its 52-week high as of September 1, 2026, keeping the medical device maker in focus while investors assess recent revenue growth and valuation metrics.

IRadimed stock (ISIN US4627231087) is trading near the top of its recent range, with a closing price of 86.35 USD as of September 1, 2026, according to a market overview on a leading financial portal. The same data show the shares within a broader context of healthcare names that have delivered strong year-to-date gains by early September 2026.

Valuation and recent price levels

According to a quote page from Morningstar updated as of September 1, 2026, IRadimed shares closed at 86.35 USD, compared with a stated fair value estimate of 77.19 USD. The same source notes that in a recent prior session the stock traded as high as 102.59 USD, with a 52-week range from 47.48 USD to 102.59 USD, underlining how far the price has recovered from its lows over the past year. For investors, this means the current level is clearly closer to the 52-week high than to the 52-week low, a sign of sustained positive sentiment toward the company.

The Morningstar data also highlight that the previous close in that earlier session stood at 100.86 USD, implying that the more recent 86.35 USD level as of September 1, 2026 represents a pullback of 14.51 USD from that peak level. This quantified comparison underscores how the stock remains elevated in a longer term perspective while still showing episodes of volatility in late August and early September 2026. Such swings are typical for a smaller medical technology name and can offer both risk and opportunity depending on an investor's time horizon.

Fundamentals and latest reported figures

While intraday and daily prices are updated continuously, fundamental figures for IRadimed come from the company’s most recent quarterly and annual reports, which cover periods ending within the last two years relative to September 2, 2026. Financial portals that track the stock summarize the latest reported annual revenue and earnings per share, providing a baseline for valuation metrics such as the price to earnings ratio and revenue multiples as of the most recent complete fiscal year.

According to the same Morningstar coverage, the market capitalization associated with IRadimed’s listing on Nasdaq reflects a valuation in the range that corresponds to the observed share price of 86.35 USD as of September 1, 2026 and the company’s reported share count. This market capitalization has increased significantly compared with the levels implied by the 52-week low of 47.48 USD, meaning that investors have assigned a higher overall value to the business over the last 12 months, even after the pullback from the intrayear high of 102.59 USD.

Medical device focus and growth drivers

IRadimed focuses on medical devices that support patient monitoring and related applications, a niche that benefits from ongoing investments in hospital and clinic infrastructure. The company’s products are designed to operate safely in demanding environments, supporting clinicians in gathering accurate physiological data. This specialized positioning helps explain why investors are willing to value the stock near its 52-week high as of early September 2026, even in a broader market where some healthcare names have already priced in strong growth expectations.

For shareholders, the key questions over the coming quarters will center on whether IRadimed can continue to grow revenue and maintain or improve its margins, thereby justifying a share price that remains well above the 52-week low. If the company reports further increases in sales and profitability in its upcoming quarterly updates, the valuation supported by a price in the mid 80 USD range as of September 1, 2026 could appear more sustainable. Conversely, any slowdown in growth would likely be reflected in a narrower gap between the current price and the 52-week low.

IRadimed devices in clinical use

One representative example of IRadimed’s offering is its suite of patient monitoring systems intended for use in hospital settings, including areas where standard equipment faces technical limitations. These devices are designed to combine reliability with safety, allowing clinicians to monitor vital signs without compromising patient care. As healthcare providers continue to invest in upgrading their equipment, such specialized devices can play a role in supporting long term revenue growth for the company.

IRadimed stock price snapshot

Based on the Morningstar quotation, IRadimed stock closed at 86.35 USD on Nasdaq as of September 1, 2026, with that date representing the latest completed trading session in the available data set. With a 52-week range from 47.48 USD to 102.59 USD, the current level leaves the shares closer to their recent high than to the low, highlighting how the market continues to price in growth expectations for the medical device maker.

IRadimed stock facts

• Company: IRadimed Corporation
• ISIN: US4627231087
• Ticker: IRMD
• Trading venue: Nasdaq
• Price (as of September 1, 2026): 86.35 USD
• Sector / Industry: Health Care / Medical Devices
• Index membership: None